Th1 responses are more susceptible to infliximab-mediated immunosuppression than Th17 responses

Medicine and Dentistry

• Tumor Necrosis Factor 100%
• Infliximab 83%
• Th1 Cell 33%
• Th17 Cell 33%
• Cells 25%
• Secretion (Process) 25%
• Interleukin 17 25%
• Interferon 16%
• In Vitro 16%
• TUNEL Assay 16%
• Programmed Cell Death 16%
• T-Helper Cell 16%
• Lipocortin 5 16%
• Deoxyuridine 16%
• Immunoglobulin G1 16%
• Macrophage 8%
• Inpatient 8%
• Pathogenesis 8%
• Therapeutic Procedure 8%
• Differentiation 8%
• Necrosis 8%
• Assay 8%
• DNA Nucleotidylexotransferase 8%
• T Cell 8%
• Antibody 8%
• Flow Cytometry 8%
• Blood 8%
• Volunteer 8%
• Culture 8%
• Inflammatory Bowel Disease 8%
• Enzyme Linked Immunosorbent Assay 8%
• Immunosuppressive Treatment 8%
• Mechanism of Action 8%
• Gut 8%
• Interferon Production 8%
• Patient with Inflammatory Bowel Disease 8%

Immunology and Microbiology

• Infliximab 83%
• Th1 Cell 33%
• Th17 Cell 33%
• Secretion (Process) 25%
• Interleukin 17 25%
• Interferon Type I 16%
• Cells 16%
• Macrophage 16%
• Apoptosis 16%
• Inflammatory Bowel Disease 16%
• Immunoglobulin G1 16%
• Differentiation 8%
• Supernatant 8%
• Monospecific Antibody 8%
• Blood Product 8%
• Staining 8%
• Normal Human 8%
• ELISA 8%
• Interferon Production 8%
• Percentage of Apoptotic Cells 8%

Neuroscience

• Inflammatory Bowel Disease 16%
• Deoxyuridine 16%
• Immunoglobulin G1 16%
• DNA Nucleotidylexotransferase 8%